<DOC>
	<DOCNO>NCT01267084</DOCNO>
	<brief_summary>The purpose study evaluate potential effect ketoconazole blood level trabectedin administration patient advanced malignancy .</brief_summary>
	<brief_title>A Study Assess Potential Effects Ketoconazole Pharmacokinetics Trabectedin Patients With Advanced Malignancies</brief_title>
	<detailed_description>This open-label study ( patient know name study drug receive ) , randomize ( patient assign 1 2 treatment sequence chance ) design examine pharmacokinetics ( blood level ) trabectedin coadministered ketoconazole patient advanced malignancy . Study drug include trabectedin ketoconazole . Trabectedin drug develop treat patient cancer administer intravenously ( IV ) catheter ( tube ) central vein period 3 hour every 21 day without ketoconazole . Ketoconazole antifungal agent take tablet orally ( mouth ) , may interfere metabolism trabectedin . In addition , dexamethasone equivalent steroid , drug use prevent nausea vomit chemotherapy patient may protective effect liver , administer patient administration trabectedin treatment cycle . This study consist 2 part , Part A B . In Part A , trabectedin+ketoconazole follow trabectedin alone administer ketoconazole 4 patient evaluate safety . If safety PK data collect Part A deem acceptable , enrollment Part B study begin patient receive 1 2 treatment sequence trabectedin ketoconazole . Patients Part A Part B complete treatment phase study discontinue due ketoconazole toxicity , opinion investigator would derive overall clinical benefit treatment trabectedin opportunity continue treatment trabectedin optional extension phase . The dose schedule trabectedin may modify treat physician optional extension phase appropriate type malignancy treat . Patients receive 20 mg IV dexamethasone equivalent steroid prior trabectedin administration cycle . Part A consists ketoconazole 200mg 2x daily+trabectedin 0.2mg/m2 i.v . follow 21 day later trabectedin 1.3mg/m2 i.v . Part B consist Sequence 1 ( ketoconazole 200mg 2x daily+trabectedin 0.2mg/m2 i.v.followed 21 day later trabectedin 1.3mg/m2 i.v . ) Sequence 2 ( trabectedin 1.3mg/m2 i.v follow 21 day later ketoconazole 200mg 2x daily+trabectedin 0.2mg/m2 i.v ) . Dexamethasone 20mg i.v . equivalent , give 30 minute trabectedin cycle .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Patients locally advance metastatic disease , solid tumor except hepatocellular carcinoma ( cancer liver ) , relapse progressive disease follow standard care treatment chemotherapy prior enrollment , intolerant prior standard care treatment chemotherapy Patients previous exposure trabectedin Patients cancer metastasize ( spread ) central nervous system Patients know liver disease Patients myocardial infarct ( heart attack ) within 6 month enrollment clinically significant unstable medical condition assess Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Trabectedin ( YONDELIS )</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Locally advanced metastatic disease</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>